| Ticker Symbol: | EXEL |
|---|---|
| Exchange: | NASD |
| Contact Info: | 170 Harbor Way South San Francisco CA 94083 650 837-7000 |
| CEO/President: | Vincent Marchesi M |
| Industry: | Medical - Biomedical / Standard Industry Code: 8731 |
| Description: | Exelixis Inc. is a leader in the fields of model system genetics andcomparative genomics. These fields involve the systematic study of simpleorganisms, such as fruit flies, nematodes, mice, zebrafish and simple plants, to rapidly and efficiently determine gene function and establish its commercial utility in humans and other commercially important biological systems. The proprietary technologies provide a rapid, efficient and cost-effective way to move beyond DNA sequence data to understand the function of genes and the proteins that they encode. |
| Shares Outstanding: | 106,650 (000) | Market Value: | 325,290 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 86.33% | Number of Inst.Shareholders: | 6.41% |
| Last Quarter Sales: | 29.93 ($Mil.) | Last Quarter Net Income: | -38.51 ($Mil.) |
| Last Quarter EPS: | -0.39 | P/E Ratio: | 0 |
| Most Recent Earnings: | -0.36 on 10/27/08 | Earnings Per Share: | -1.37 |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |


| AMGEN | +12.60 | 58.23 | |
| GILEAD SCIENCES | -1.00 | 46.92 | |
| CELGENE CP | -10.00 | 58.86 | |
| BIOGEN IDEC INC | -31.90 | 43.52 | |
| AMYLIN PHARMA I | -85.70 | 6.41 |
